Impel Pharmaceuticals Inc. (NASDAQ:IMPL) Q1 2023 Earnings Conference Call May 12, 2023 8:30 AM ET

Company Participants

Adrian Adams - Chairman and Chief Executive Officer

Michael Kalb - Chief Financial Officer

Leonard Paolillo - Chief Commercial Officer

Rajiv Amin - Controller

Conference Call Participants

Stacy Ku - TD Cowen

Eddie Hickman - Guggenheim Securities

Sean Kim - Jones Trading

Operator

Good morning, ladies and gentlemen and welcome to Impel Pharmaceuticals First Quarter 2023 Earnings and Business Update Conference Call. At this time, all participants are in a listen-only mode. Later in this call a question-and-answer session will be conducted and instructions on how to participate will be given at that time. As a reminder, today's conference call is being recorded.

And now I would like to turn the conference over to Impel's Chairman and Chief Executive Officer, Mr. Adrian Adams. Mr. Adams please go ahead.

Adrian Adams

Thank you, operator and good morning everyone. We are delighted that you could join us today for Impel Pharmaceuticals' earnings conference call to review our first quarter 2023 commercial and financial results, as well as to provide a general business update in addition to highlighting the key priorities for Impel for the remainder of 2023. Joining me from Impel this morning is Len Paolillo, our Chief Commercial Officer; Rajiv Amin, our Controller and our new Chief Financial Officer, Michael Kalb.

Michael brings to Impel and ascending track record of executive leadership in pharma, capital raising, business development, and operations management and we are thrilled to have someone of his caliber and experience join our leadership team at this critical phase of our evolution.

Before we begin, I would like to remind everyone that we have a slide presentation to accompany our conference call this morning which can be viewed on our website at www.impelpharma.com. If you are listening to this call on your telephone, you may access a synchronized slide deck on our website by choosing the link on our webcast page that says Click Here to listen.

I would also like to remind you that during this call, the company will be making forward-looking statements that are subject to risks and uncertainties that may cause actual results to differ from the results discussed in the forward-looking statements.

Now I'd like to turn to Slide number 4 where I will summarize our first quarter and year-to-date performance with Trudhesa. Firstly, I would like to remind everyone of the tremendous opportunity that exists within this large migraine market. This is a market growing 10% year-over-year and becoming increasingly branded with most of that growth coming from newer non-triptan options.